Home LiteratureArticle Details
PMID: 15831913 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Placenta growth factor expression is correlated with survival of patients with colorectal cancer.

Gut ·Vol. 54 ·No. 5 ·2005-05-00 ·Pages 666-72

Wei SC, Tsao PN, Yu SC, Shun CT, Tsai-Wu JJ, Wu CH, Su YN, Hsieh FJ, Wong JM

Abstract

Overexpression of vascular endothelial growth factor (VEGF) correlates with vascularity, metastasis, and proliferation in colorectal cancer but the role of its homologue, placenta growth factor (PlGF), is unknown. The aim of this study was to evaluate expression and clinical implications of PlGF in colorectal cancer. We investigated 74 tumour/non-tumour pairs of colorectal cryosections. Clinical staging was based on the UICC-TNM classification. Expression levels of mRNA for PlGF and VEGF were analysed with quantitative real time reverse transcription-polymerase chain reaction. Proteins were analysed by immunohistochemical staining and enzyme linked immunoabsorbant assay. Analysis of the differences in PlGF and VEGF levels between tumour and non-tumour tissues in the same patient were performed by paired t test; differences between localised and advanced disease patients by the Mann-Whitney, chi(2), and Fisher's exact tests and survival curves by the Kaplan-Meier method. Expression levels for both growth factors were significantly higher in tumour than in non-tumour tissues (p</=0.001). The ratio of PlGF expression in tumour to non-tumour in the advanced disease group was significantly higher than for the localised disease group (p = 0.009). Patients with more tumour PlGF mRNA had shorter survival (p = 0.028). The majority of PlGF was expressed in tumour cells. Our results suggest that PlGF expression correlates with disease progression and patient survival and may be used as a prognostic indicator for colorectal cancer.

MeSH Terms
Adult Aged Aged, 80 and over Biomarkers, Tumor/genetics,metabolism Colorectal Neoplasms/metabolism,mortality Disease Progression Female Humans Immunoenzyme Techniques Male Middle Aged Neoplasm Proteins/genetics,metabolism Placenta Growth Factor Pregnancy Proteins/genetics,metabolism Prognosis RNA, Messenger/genetics RNA, Neoplasm/genetics Reverse Transcriptase Polymerase Chain Reaction/methods Survival Analysis Up-Regulation Vascular Endothelial Growth Factors/genetics,metabolism
Chemicals
Biomarkers, Tumor Neoplasm Proteins PGF protein, human Pregnancy Proteins RNA, Messenger RNA, Neoplasm Vascular Endothelial Growth Factors Placenta Growth Factor
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Wei S-C
Department of Internal Medicine, National Taiwan University Hospital, No 7 Chung Shan South Rd, Taipei, Taiwan.
Tsao P-N
Yu S-C
Shun C-T
Tsai-Wu J-J
Wu C H H
Su Y-N
Hsieh F-J
Wong J-M
References (36)
36 references, click to expand
  1. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
    J Clin Oncol. 2003 Jan 1;21(1):60-5 PMID: 12506171
  2. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor.
    Cancer Res. 1999 Aug 15;59(16):4129-35 PMID: 10463618
  3. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.
    Science. 2003 Feb 7;299(5608):890-3 PMID: 12574630
  4. Expression and function of placenta growth factor: implications for abnormal placentation.
    J Soc Gynecol Investig. 2003 May;10(4):178-88 PMID: 12759145
  5. The biology of VEGF and its receptors.
    Nat Med. 2003 Jun;9(6):669-76 PMID: 12778165
  6. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.
    Nat Med. 2003 Jul;9(7):936-43 PMID: 12796773
  7. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders.
    J Thromb Haemost. 2003 Jul;1(7):1356-70 PMID: 12871269
  8. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
    Nat Med. 2004 Feb;10(2):145-7 PMID: 14745444
  9. Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?
    Biochim Biophys Acta. 2004 Mar 4;1654(1):79-94 PMID: 14984769
  10. Microsatellite instability and hMLH1 and hMSH2 gene expression in Taiwanese hereditary nonpolyposis colorectal cancer.
    J Formos Med Assoc. 2004 May;103(5):331-6 PMID: 15216397
  11. Regulators of angiogenesis.
    Annu Rev Physiol. 1991;53:217-39 PMID: 1710435
  12. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.
    Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9267-71 PMID: 1924389
  13. A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta.
    Growth Factors. 1993;9(4):259-68 PMID: 8148155
  14. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.
    Cancer Res. 1994 Aug 1;54(15):4233-7 PMID: 7518352
  15. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.
    J Biol Chem. 1994 Oct 14;269(41):25646-54 PMID: 7929268
  16. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.
    Cancer Res. 1995 Sep 15;55(18):3964-8 PMID: 7664263
  17. Angiogenesis in cancer, vascular, rheumatoid and other disease.
    Nat Med. 1995 Jan;1(1):27-31 PMID: 7584949
  18. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor.
    J Clin Invest. 1996 Dec 1;98(11):2507-11 PMID: 8958213
  19. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.
    Cell. 1996 Aug 9;86(3):353-64 PMID: 8756718
  20. Localisation of placenta growth factor (PIGF) in human term placenta.
    Growth Factors. 1996;13(3-4):243-50,color plates I-II,pre.bk cov PMID: 8919031
  21. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis.
    J Clin Invest. 1997 May 15;99(10):2351-7 PMID: 9153276
  22. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer.
    Int J Cancer. 1998 Feb 20;79(1):34-8 PMID: 9495355
  23. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer.
    Br J Cancer. 1998 Sep;78(6):765-70 PMID: 9743297
  24. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression.
    Int J Cancer. 1999 Jun 11;81(6):845-50 PMID: 10362127
  25. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa.
    Int J Cancer. 2000 Apr 15;86(2):174-81 PMID: 10738243
  26. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients.
    Eur J Cancer. 2000 Apr;36(6):748-53 PMID: 10762747
  27. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review.
    Placenta. 2000 Mar-Apr;21 Suppl A:S16-24 PMID: 10831117
  28. Angiogenesis in cancer and other diseases.
    Nature. 2000 Sep 14;407(6801):249-57 PMID: 11001068
  29. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.
    Nat Med. 2001 May;7(5):575-83 PMID: 11329059
  30. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.
    Nat Genet. 2001 Jun;28(2):131-8 PMID: 11381259
  31. Placental growth factor is a survival factor for tumor endothelial cells and macrophages.
    Cancer Res. 2002 May 15;62(10):2749-52 PMID: 12019148
  32. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF.
    Hypertension. 2002 Jun;39(6):1095-100 PMID: 12052848
  33. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice.
    Nat Med. 2002 Jul;8(7):702-10 PMID: 12053176
  34. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.
    Nat Med. 2002 Aug;8(8):831-40 PMID: 12091877
  35. Expression and localization of placenta growth factor and PlGF receptors in human meningiomas.
    J Pathol. 1999 Sep;189(1):66-71 PMID: 10451490
  36. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis.
    Cancer. 2003 Feb 15;97(4):960-8 PMID: 12569594
Article Info
Journal
Gut
Abbr.
Gut
ISSN
0017-5749
DOI
10.1136/gut.2004.050831
Published
2005-05-00
Pages
666-72
Language
English
Region
England
NLM ID
2985108R
PMCID
PMC1774482
Subset
IM
External Links
PubMed source DOI: 10.1136/gut.2004.050831 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2